Individualizing Immune Modulation & Chemotherapy (i2mc)

Stein Bergan<br>Group leader
Stein Bergan
Group leader

Research aims

Overall aim: To establish and document principles for individualized dosing in selected pharmacotherapies, mainly those related to immunosuppression and chemotherapy, also including anti-infectives and statins which target complications in immunosuppression. 

This may be achieved by:

  • The combination of pharmacokinetics (PK), pharmacodynamics (PD) and pharmacogenomics (PGx), sources for individual variability in the response of specific drugs.
  • The identification of variant genotypes or altered gene expression affecting drug response. Biomarkers for the above.
  • Models for decision support, including population PK/PD models and integrative models for biomarkers.

Current projects

  • Belatacept in kidney transplantation (Erasmus MC, Rotterdam)
  • Tacrolimus new PK/PD principles for individualization (Dept of Transplant Medicine)
  • MarkIT pilot study on biomarkers for tacrolimus and mycophenolate in renal transplant recipients (Dept of Transplant Medicine)
  • Pharmacogenetic panels; High throughput screening (Dept of Genetics)
  • Pediatric and adult hemato-oncology and transplantation, e.g. busulfan, glucocorticoids, tacrolimus (Dept of Pediatrics; Dept of Hematology)
  • Immunosuppressants and pancreatic islets (Institute of Surgical Research, UiO)
  • Personalized statin treatment (Dept of Medicine, Drammen Hospital)

Contact information

Group leader 
Stein Bergan, Department of Pharmacology
Tel: +47 23071082; 93266214
E-mail: /